Anhydrous enol oxaloacetate is under clinical development by MetVital and currently in Phase II for Fatigue. According to GlobalData, Phase II drugs for Fatigue does not have sufficient historical ...

Efgartigimod alfa is under clinical development by Argenx and currently in Phase II for Guillain-Barre Syndrome.

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

Central Pacific Bank Trust Division bought a new position in argenx SE (NASDAQ:ARGX – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

The prevalence and incidence rates of myasthenia gravis in the elderly US population have increased from 2006 to 2019.

For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

SPRINGFIELD, Ill. – The Illinois Department of Public Health (IDPH) has approved four new conditions for treatment with ...